Drug Approval | February 20, 2026
Johnson & Johnson bags FDA nod for monthly RYBREVANT FASPRO dosing in advanced lung cancer
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
The VELO system supports multiplex testing for Influenza A, Influenza B, and COVID-19, producing PCR results in six to ten minutes
Subscribe To Our Newsletter & Stay Updated
